Participants
ONCOLOGY, DISEASE, DISORDER
Patients were ≥ 18 years old with unresectable advanced, recurrent or metastatic solid tumor bearing documented FGF/FGFR alterations, and had failed to prior therapy or no standard therapy available. Patients had at least one measurable lesion, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and an anticipated life expectancy of ≥ 12 weeks. Patients who previously received the selective FGFR inhibitor were excluded. Other key exclusion criteria included history of calcium and phosphate hemostasis disorder, and ophthalmologically confirmed corneal/retinal disease (with clinical significance).